title: [Mechanisms for formation of myeloma bone disease].
abstract: Myeloma cells stimulate bone resorption by enhancing osteoclast formation and suppress bone formation by inhibiting osteoblast differentiation. Macrophage inflammatory protein (MIP)-1alpha and MIP-1beta as well as RANK ligand play a major role in the enhancement of bone resorption in myeloma. Myeloma cell-derived soluble Wnt inhibitors as well as TGF-beta released from the bone tissues through enhanced bone resorption are thought to suppress osteoblast differentiation. Such pathognomonically skewed cellular components in the bone marrow create a microenvironment suitable for myeloma cell growth and survival (a myeloma niche) , which should be targeted to suppress myeloma expansion along with amelioration of bone lesions.
authors: University of Tokushima Graduate School of Medicine, Department of Medicine and Bioregulatory Sciences.
authors: Kenichiro
authors: K
authors: Yata
authors: Masahiro
authors: M
authors: Abe
authors: Toshio
authors: T
authors: Matsumoto
mesh_terms: D001862:Bone Resorption / Q000209:etiology* / Q000473:pathology; D001842:Bone and Bones / Q000473:pathology; D002454:Cell Differentiation; D054405:Chemokine CCL3 / Q000502:physiology; D054407:Chemokine CCL4 / Q000502:physiology; D006801:Humans; D009101:Multiple Myeloma / Q000150:complications* / Q000473:pathology; D010006:Osteoblasts / Q000166:cytology; D010010:Osteoclasts / Q000502:physiology; D010012:Osteogenesis; D053245:RANK Ligand / Q000502:physiology; D016212:Transforming Growth Factor beta / Q000502:physiology
chemical_list: C515429:CCL3 protein, human; D054405:Chemokine CCL3; D054407:Chemokine CCL4; D053245:RANK Ligand; D016212:Transforming Growth Factor beta